RESUMEN
In this study, we outlined the green synthesis of Zinc oxide nanoparticles (ZnO NPs) using the plant-mediated method. Employing the nitrate derivative of Zinc and the extract from the native medicinal plant, Ottonia anisum, the nanoparticles were effectively produced. After obtaining a yellow-colored paste, it was meticulously dried, gathered, and set aside for subsequent examination. The UV-visible spectrometry analysis indicated an absorption peak at 320 nm, which is indicative of ZnO NPs. Characterization techniques, such as XRD and HR-TEM, confirmed the existence of agglomerated ZnO NPs with an average diameter of 40 nm. Through EDS analysis, distinct energy signals for both Zinc and Oxygen were observed, confirming their composition. Furthermore, FT-IR spectroscopy highlighted an absorption peak for Zn-O bonding in the range of 400 to 600 cm -1 . Further, we employed three distinct pain models in mice to evaluate the influence of ZnO NPs on the nociceptive threshold. Our findings revealed that, when orally administered, ZnO NPs at concentrations ranging from 5-20 mg/kg exerted a dose-dependent analgesic effect in both the hot-plate and the acetic acid-induced writhing tests. Moreover, when ZnO NPs were administered at doses between 2.5-10 mg/kg, there was a notable reduction in pain responses during both the initial and subsequent phases of the formalin test, but no change in PGE 2 production within the mice's hind paw was found. On the other hand, acute lung injury studies revealed that the administration of ZnO NPs orally 90 minutes prior to HCl instillation decreased the neutrophil infiltration into the lungs in a doseresponsive manner. This reduction in pulmonary inflammation was paralleled by a significant decrease in lung edema, as evidenced by the reduced total protein content in the BALF. Additionally, the ZnO NPs appeared to recalibrate the lung's redox equilibrium following HCl exposure, which was determined through measurements of ROS, malondialdehyde, glutathione, and catalase activity. All these results further indicated the potential of biofabricated ZnO NPs for future applications in analgesics and acute lung injury treatments.
Asunto(s)
Lesión Pulmonar Aguda , Analgésicos , Extractos Vegetales , Óxido de Zinc , Animales , Extractos Vegetales/química , Extractos Vegetales/farmacología , Analgésicos/síntesis química , Analgésicos/farmacología , Lesión Pulmonar Aguda/tratamiento farmacológico , Lesión Pulmonar Aguda/inducido químicamente , Ratones , Masculino , Nanopartículas del Metal/química , Tecnología Química Verde , Relación Dosis-Respuesta a Droga , Modelos Animales de Enfermedad , Dolor/tratamiento farmacológico , Dolor/inducido químicamente , Ácido AcéticoRESUMEN
P2X3 receptors (P2X3R) are ATP-gated ion channels predominantly expressed in C- and Aδ-fiber primary afferent neurons and have been introduced as a novel therapeutic target for neurological disorders, including neuropathic pain and chronic cough. Because of its localized distribution, antagonism of P2X3R has been thoroughly considered, and the avoidance of issues related to CNS side effects has been proven in clinical trials. In this article, benzimidazole-4,7-dione-based derivatives were introduced as a new chemical entity for the development of P2X3R antagonists. Starting from the discovery of a hit compound from the screening of 8364 random library compounds in the Korea Chemical Bank, which had an IC50 value of 1030 nM, studies of structure-activity and structure-property relationships enabled further optimization toward improving the antagonistic activities as well as the drug's physicochemical properties, including metabolic stability. As for the results, the final optimized compound 14h was developed with an IC50 value of 375 nM at P2X3R with more than 23-fold selectivity versus P2X2/3R, along with properties of metabolic stability and improved solubility. In neuropathic pain animal models evoked by either nerve ligation or chemotherapeutics in male Sprague-Dawley rats, compound 14h showed anti-nociceptive effects through an increase in the mechanical withdrawal threshold as measured by von Frey filament following intravenous administration.
Asunto(s)
Analgésicos/química , Analgésicos/farmacología , Bencimidazoles/química , Bencimidazoles/farmacología , Antagonistas del Receptor Purinérgico P2X/química , Antagonistas del Receptor Purinérgico P2X/farmacología , Analgésicos/síntesis química , Animales , Bencimidazoles/síntesis química , Técnicas de Química Sintética , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Evaluación Preclínica de Medicamentos , Monitoreo de Drogas , Humanos , Ratones , Estructura Molecular , Antagonistas del Receptor Purinérgico P2X/síntesis química , Ratas , Bibliotecas de Moléculas Pequeñas , Relación Estructura-ActividadRESUMEN
The rising opioid crisis has become a worldwide societal and public health burden, resulting from the abuse of prescription opioids. Targeting the κ-opioid receptor (KOR) in the periphery has emerged as a powerful approach to develop novel pain medications without central side effects. Inspired by the traditional use of sunflower (Helianthus annuus) preparations for analgesic purposes, we developed novel stabilized KOR ligands (termed as helianorphins) by incorporating different dynorphin A sequence fragments into a cyclic sunflower peptide scaffold. As a result, helianorphin-19 selectively bound to and fully activated the KOR with nanomolar potency. Importantly, helianorphin-19 exhibited strong KOR-specific peripheral analgesic activity in a mouse model of chronic visceral pain, without inducing unwanted central effects on motor coordination/sedation. Our study provides a proof of principle that cyclic peptides from plants may be used as templates to develop potent and stable peptide analgesics applicable via enteric administration by targeting the peripheral KOR for the treatment of chronic abdominal pain.
Asunto(s)
Dolor Abdominal/tratamiento farmacológico , Analgésicos/farmacología , Péptidos Cíclicos/farmacología , Extractos Vegetales/farmacología , Receptores Opioides kappa/antagonistas & inhibidores , Analgésicos/síntesis química , Analgésicos/química , Animales , Células Cultivadas , Enfermedad Crónica , Relación Dosis-Respuesta a Droga , Diseño de Fármacos , Células HEK293 , Helianthus/química , Humanos , Masculino , Ratones , Ratones Endogámicos C57BL , Estructura Molecular , Péptidos Cíclicos/síntesis química , Péptidos Cíclicos/química , Extractos Vegetales/síntesis química , Extractos Vegetales/química , Receptores Opioides kappa/metabolismo , Semillas/química , Relación Estructura-ActividadRESUMEN
The new series of 3-(2-chlorophenyl)- and 3-(3-chlorophenyl)-pyrrolidine-2,5-dione-acetamide derivatives as potential anticonvulsant and analgesic agents was synthesized. The compounds obtained were evaluated in the following acute models of epilepsy: maximal electroshock (MES), psychomotor (6 Hz, 32 mA), and subcutaneous pentylenetetrazole (scPTZ) seizure tests. The most active substance-3-(2-chlorophenyl)-1-{2-[4-(4-fluorophenyl)piperazin-1-yl]-2-oxoethyl}-pyrrolidine-2,5-dione (6) showed more beneficial ED50 and protective index values than the reference drug-valproic acid (68.30 mg/kg vs. 252.74 mg/kg in the MES test and 28.20 mg/kg vs. 130.64 mg/kg in the 6 Hz (32 mA) test, respectively). Since anticonvulsant drugs are often effective in neuropathic pain management, the antinociceptive activity for two the promising compounds-namely, 6 and 19-was also investigated in the formalin model of tonic pain. Additionally, for the aforementioned compounds, the affinity for the voltage-gated sodium and calcium channels, as well as GABAA and TRPV1 receptors, was determined. As a result, the most probable molecular mechanism of action for the most active compound 6 relies on interaction with neuronal voltage-sensitive sodium (site 2) and L-type calcium channels. Compounds 6 and 19 were also tested for their neurotoxic and hepatotoxic properties and showed no significant cytotoxic effect.
Asunto(s)
Analgésicos/síntesis química , Analgésicos/farmacología , Anticonvulsivantes/síntesis química , Anticonvulsivantes/farmacología , Pirrolidinas/síntesis química , Pirrolidinas/farmacología , Analgésicos/química , Animales , Anticonvulsivantes/química , Línea Celular , Modelos Animales de Enfermedad , Evaluación Preclínica de Medicamentos , Células Hep G2 , Humanos , Técnicas In Vitro , Masculino , Ratones , Estructura Molecular , Neuralgia/tratamiento farmacológico , Pirrolidinas/química , Convulsiones/tratamiento farmacológico , Relación Estructura-ActividadRESUMEN
More than 500 molecules have been identified as components of Cannabis sativa (C. sativa), of which the most studied is Δ9-tetrahydrocannabinol (Δ9-THC). Several studies have suggested that Δ9-THC exerts diverse biological effects, ranging from fragmentation of DNA to behavioral disruptions. Currently, it is accepted that most of the pharmacological properties of Δ9-THC engage the activation of the cannabinoid receptors, named CB1 and CB2. Interestingly, multiple pieces of evidence have suggested that the cannabinoid receptors play an active role in the modulation of several diseases leading to the design of synthetic cannabinoid-like compounds. Advances in the development of synthetic CB1 cannabinoid receptor selective agonists as therapeutical approaches are, however, limited. This review focuses on available evidence searched in PubMed regarding the synthetic CB1 cannabinoid receptor selective agonists such as AM-1235, arachidonyl-2' chloroethylamide (ACEA), CP 50,556-1 (Levonantradol), CP-55,940, HU-210, JWH-007, JWH-018, JWH-200 (WIN 55,225), methanandamide, nabilone, O-1812, UR-144, WIN 55,212-2, nabiximols, and dronabinol. Indeed, it would be ambitious to describe all available evidence related to the synthetic CB1 cannabinoid receptor selective agonists. However, and despite the positive evidence on the positive results of using these compounds in experimental models of health disturbances and preclinical trials, we discuss evidence in regards some concerns due to side effects.
Asunto(s)
Agonistas de Receptores de Cannabinoides/síntesis química , Agonistas de Receptores de Cannabinoides/uso terapéutico , Sustancias Controladas/síntesis química , Receptor Cannabinoide CB1/agonistas , Analgésicos/síntesis química , Analgésicos/uso terapéutico , Animales , Ansiolíticos/síntesis química , Ansiolíticos/uso terapéutico , Cannabinoides/síntesis química , Cannabinoides/uso terapéutico , Sustancias Controladas/administración & dosificación , Ciclohexanoles/síntesis química , Ciclohexanoles/uso terapéutico , Dronabinol/análogos & derivados , Dronabinol/síntesis química , Dronabinol/uso terapéutico , Humanos , Trastornos Mentales/tratamiento farmacológico , Trastornos Mentales/metabolismo , Dolor/tratamiento farmacológico , Dolor/metabolismo , Fenantridinas/síntesis química , Fenantridinas/uso terapéutico , Receptor Cannabinoide CB1/metabolismoRESUMEN
The cool sensor transient receptor potential melastatin channel 8 (TRPM8) is highly expressed in trigeminal and dorsal root ganglia, playing a key role in cold hypersensitivity associated to different peripheral neuropathies. Moreover, these channels are aberrantly expressed in different cancers, and seem to participate in tumor progression, survival and invasion. Accordingly, the search for potent and selective TRPM8 modulators attracted great interest in recent years. We describe new heterocyclic TRPM8 antagonist chemotypes derived from N-cloroalkyl phenylalaninol-Phe conjugates. The cyclization of these conjugates afforded highly substituted ß-lactams and/or 2-ketopiperazine (KP) derivatives, with regioselectivity depending on the N-chloroalkyl group and the configuration. These derivatives behave as TRPM8 antagonists in the Ca2+ microfluorometry assay, and confirmed electrophysiologically for the best enantiopure ß-lactams 24a and 29a (IC50, 1.4 and 0.8 µM). Two putative binding sites by the pore zone, different from those found for typical agonists and antagonists, were identified by in silico studies for both ß-lactams and KPs. ß-Lactams 24a and 29a display antitumor activity in different human tumor cell lines (micromolar potencies, A549, HT29, PSN1), but correlation with TRPM8 expression could not be established. Additionally, compound 24a significantly reduced cold allodynia in a mice model of oxaliplatin-induced peripheral neuropathy.
Asunto(s)
Analgésicos/uso terapéutico , Antineoplásicos/uso terapéutico , Hiperalgesia/tratamiento farmacológico , Piperazinas/uso terapéutico , Canales Catiónicos TRPM/antagonistas & inhibidores , beta-Lactamas/uso terapéutico , Analgésicos/síntesis química , Analgésicos/farmacología , Animales , Antineoplásicos/síntesis química , Antineoplásicos/farmacología , Línea Celular Tumoral , Frío/efectos adversos , Simulación por Computador , Citofotometría , Evaluación Preclínica de Medicamentos , Masculino , Ratones , Modelos Moleculares , Simulación del Acoplamiento Molecular , Estructura Molecular , Oxaliplatino/toxicidad , Técnicas de Placa-Clamp , Enfermedades del Sistema Nervioso Periférico/inducido químicamente , Enfermedades del Sistema Nervioso Periférico/tratamiento farmacológico , Piperazinas/síntesis química , Piperazinas/farmacología , Relación Estructura-Actividad , beta-Lactamas/síntesis química , beta-Lactamas/farmacologíaRESUMEN
In this study, we synthesised the zinc oxide nanoparticles from Vernonia amygdalina and evaluated its anti-inflammatory and antinociceptive potentials against the different inflammation and pain induced mice model. The synthesised zinc oxide nanoparticles were characterised by UV, SEM, XRD and FTIR techniques. The anti-nociceptive effects of V. amygdalina were examined by different stimuli e.g. acetic acid, glutamate, capsaicin, and formalin-induced nociception in mice. The anti-inflammatory effects of synthesised zinc oxide nanoparticles were assessed by air sack assessment and the level of inflammatory cytokines were studied. The muscle tension of animals were studied through open field assessment. The present study exhibited proficient antinociceptive and anti-inflammatory actions of the synthesised Zinc oxide nanoparticles from V. amygdalina. The sormulated zinc oxide nanoparticles were appreciably reduced the acetic acid, glutamate, capsaicin, and formalin-induced nociceptive responses in mice. Further the zinc nanoparticles were exhibited the potent anti-inflammatory actions via reducing the inflammatory response and pro-inflammatory cytokines level in the mice. In conclusion, the findings of this study proved the beneficial effects of zinc oxide nanoparticles from V. amygdalina against the different pain and inflammation-induced mice. Hence, it was clear that the zinc nanoparticles from V. amygdalina could be promising antinociceptive and anti-inflammatory agent in the future.
Asunto(s)
Nanopartículas/química , Extractos Vegetales/química , Vernonia/química , Óxido de Zinc/síntesis química , Óxido de Zinc/farmacología , Analgésicos/síntesis química , Analgésicos/química , Analgésicos/farmacología , Animales , Antiinflamatorios/síntesis química , Antiinflamatorios/química , Antiinflamatorios/farmacología , Técnicas de Química Sintética , Citocinas/metabolismo , Modelos Animales de Enfermedad , Masculino , Ratones , Nocicepción/efectos de los fármacos , Hojas de la Planta/química , Óxido de Zinc/químicaRESUMEN
The sigma-2 receptor has been cloned and identified as Tmem97, which is a transmembrane protein involved in intracellular Ca2+ regulation and cholesterol homeostasis. Since its discovery, the sigma-2 receptor has been an extremely controversial target, and many efforts have been made to elucidate the functional role of this receptor during physiological and pathological conditions. Recently, this receptor has been proposed as a potential target to treat neuropathic pain due to the ability of sigma-2 receptor agonists to relieve mechanical hyperalgesia in mice model of chronic pain. In the present work, we developed a highly selective sigma-2 receptor ligand (sigma-1/sigma-2 selectivity ratio > 1000), 1-(4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)butyl)-3-methyl-1H- benzo[d]imidazol-2(3H)-one (CM398), with an encouraging in vitro and in vivo pharmacological profile in rodents. In particular, radioligand binding studies demonstrated that CM398 had preferential affinity for sigma-2 receptor compared with sigma-1 receptor and at least four other neurotransmitter receptors sites, including the norepinephrine transporter. Following oral administration, CM398 showed rapid absorption and peak plasma concentration (Cmax) occurred within 10 min of dosing. Moreover, the compound showed adequate, absolute oral bioavailability of 29.0%. Finally, CM398 showed promising anti-inflammatory analgesic effects in the formalin model of inflammatory pain in mice. The results collected in this study provide more evidence that selective sigma-2 receptor ligands can be useful tools in the development of novel pain therapeutics and altogether, these data suggest that CM398 is a suitable lead candidate for further evaluation.
Asunto(s)
Analgésicos/farmacología , Receptores sigma/agonistas , Analgésicos/síntesis química , Analgésicos/uso terapéutico , Animales , Descubrimiento de Drogas , Evaluación Preclínica de Medicamentos , Masculino , Ratones , Ratas Sprague-DawleyRESUMEN
An alternative method to prepare 2-organylchalcogenopheno[2,3-b]pyridines was developed by the insertion of chalcogen species (selenium, sulfur or tellurium), generated inâ situ, into 2-chloro-3-(organylethynyl)pyridines by using the NaBH4 /PEG-400 reducing system, followed by an intramolecular cyclization. It was possible to obtain a series of compounds with up to 93 % yield in short reaction times. Among the synthesized products, 2-organyltelluropheno[2,3-b]pyridines have not been described in the literature so far. Moreover, the compounds 2-phenylthieno[2,3-b]pyridine (3 b) and 2-phenyltelluropheno[2,3-b]pyridine (3 c) exhibited significant antioxidant potential in different inâ vitro assays. Further studies demonstrated that compound 3 b exerted an antinociceptive effect in acute inflammatory and non-inflammatory pain models, thus indicating the involvement of the central and peripheral nervous systems on its pharmacological action. More specifically, our results suggest that the intrinsic antioxidant property of compound 3 b might contribute to attenuating the nociception and inflammatory process on local injury induced by complete Freund's adjuvant (CFA).
Asunto(s)
Analgésicos/farmacología , Antioxidantes/farmacología , Borohidruros/química , Calcógenos/química , Inflamación/tratamiento farmacológico , Dolor/tratamiento farmacológico , Polietilenglicoles/química , Analgésicos/síntesis química , Analgésicos/química , Animales , Antioxidantes/síntesis química , Antioxidantes/química , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Adyuvante de Freund/efectos adversos , Inflamación/inducido químicamente , Masculino , Ratones , Estructura Molecular , Oxidación-Reducción , Dolor/inducido químicamenteRESUMEN
Some novel derivatives of 2-alkyl 6-substituted pyridazin-3(2H)-ones were synthesized by condensation of 3,6-dichloropyridazine with the sodium salt of benzyl cyanide, followed by hydrolysis and coupling with alkyl halides. The synthesized compounds were screened as cyclooxygenase (COX)-1/COX-2 inhibitors and as analgesic and anti-inflammatory agents. Among the synthesized compounds, 6-benzyl-2-methylpyridazin-3(2H)-one (4a), 6-benzoyl-2-propylpyridazin-3(2H)-one (8b), and 6-(hydroxy(phenyl)methyl)-2-methylpyridazin-3(2H)-one (9a) displayed the highest COX-2 selectivity indices of 96, 99, and 98, respectively, and analgesic efficacies of 47%, 46%, and 45% protection, respectively. Also, compounds 4a, 8b, and 9a showed anti-inflammatory activities of 65%, 60%, and 62% inhibition of edema, respectively, at a dose of 10 mg/kg, which is higher than that of diclofenac (58% inhibition of edema).
Asunto(s)
Analgésicos/farmacología , Antiinflamatorios no Esteroideos/farmacología , Conducta Animal/efectos de los fármacos , Inhibidores de la Ciclooxigenasa/farmacología , Edema/tratamiento farmacológico , Piridazinas/farmacología , Analgésicos/síntesis química , Analgésicos/química , Animales , Antiinflamatorios no Esteroideos/síntesis química , Antiinflamatorios no Esteroideos/química , Ciclooxigenasa 1/metabolismo , Ciclooxigenasa 2/metabolismo , Inhibidores de la Ciclooxigenasa/síntesis química , Inhibidores de la Ciclooxigenasa/química , Evaluación Preclínica de Medicamentos , Ensayos de Selección de Medicamentos Antitumorales , Humanos , Ratones , Estructura Molecular , Piridazinas/síntesis química , Piridazinas/química , Ratas , Proteínas Recombinantes/metabolismo , Relación Estructura-ActividadRESUMEN
G protein-biased mu-opioid receptor (MOR) agonists have been developed as promising new potent analgesic drugs with fewer adverse side effects than standard MOR agonists. PZM21 represents a unique chemotype unrelated to known opioids, which makes it a desirable lead for modification to find analgesics with new chemical entities. In the present study, we synthesized and tested novel PZM21 derivatives as potent biased MOR agonists by introducing a benzodioxolane group to replace the hydroxybenzene of PZM21. The new compounds displayed more potent analgesic activities inâ vivo and greater bias toward G protein signaling inâ vitro than did PZM21. These results suggest that the benzodioxolane group is essential for the maintenance of bias. Compounds 7 i ((S)-1-(3-(benzo[d][1,3]dioxol-4-yl)-2-(dimethylamino)propyl)-3-phenethylurea) and 7 j ((S)-1-(3-(benzo[d][1,3]dioxol-4-yl)-2-(dimethylamino)propyl)-3-benzylurea) could serve as new leads for further modifications to find novel biased MOR agonists with greater G protein signaling potency and less ß-arrestin-2 recruitment.
Asunto(s)
Analgésicos/uso terapéutico , Dolor/tratamiento farmacológico , Receptores Opioides mu/agonistas , Analgésicos/síntesis química , Analgésicos/química , Analgésicos/farmacología , Animales , Conducta Animal/efectos de los fármacos , Modelos Animales de Enfermedad , Evaluación Preclínica de Medicamentos , Masculino , Ratones , Ratones Endogámicos ICR , Dolor/inducido químicamente , Dolor/patología , Receptores Opioides mu/metabolismo , Transducción de Señal/efectos de los fármacos , Relación Estructura-Actividad , Arrestina beta 2/metabolismoRESUMEN
Fraxinus rhynchophylla belongs to the family of Oleaceae and also called as Chinese ash wood possesses various pharmacological properties such as neuroprotective, antimicrobial, anti-inflammatory, etc. Therefore we synthesized ZnO nanoparticles using Fraxinus rhynchophylla wood extract as reducing and capping agent. The synthesized nanoparticles were characterized with the aid of UV-Spec, DLS, FT-IR and TEM analysis. Green synthesized ZnO nanoparticles were then assessed for anti-nociceptive property by using various nociception models such as thermal stress-induced, acetic acid, glutamate, capsaicin, and formalin-induced nociception. The sedative effect of synthesized ZnO nanoparticles was evaluated with an open field test. UV-Spectroscopic analysis confirms the formation of ZnO nanoparticles and the characterization studies DLS, FT-IR, and TEM analysis prove it has ideal nanoparticle can be used as a nano-drug. Results of both thermal stress-induced methods hot plate and tail immersion nociception test verified the synthesized ZnO nanoparticles are a potent antinociceptive drug. ZnO nanoparticles effectively reduced the abdominal writhes in acetic acid-induced nociception and it also significantly decreased the nociception activity in another glutamate, capsaicin, and formalin-induced nociception models. Open field experiment proved that synthesized ZnO nanoparticles are less sedative compared to the standard antinociceptive drug morphine. Overall our findings authentically confirm ZnO nanoparticles synthesized from Fraxinus rhynchophylla wood extract is a novel drug that persuasively reduces nociception in different nociceptive induced mice models and can be the best alternative for allopathic drugs which renders severe side effects.
Asunto(s)
Analgésicos/uso terapéutico , Fraxinus/química , Nanopartículas del Metal/química , Dolor/tratamiento farmacológico , Óxido de Zinc/química , Analgésicos/síntesis química , Analgésicos/química , Animales , Modelos Animales de Enfermedad , Formaldehído/toxicidad , Fraxinus/metabolismo , Tecnología Química Verde , Calor , Masculino , Nanopartículas del Metal/uso terapéutico , Ratones , Dolor/inducido químicamente , Corteza de la Planta/química , Corteza de la Planta/metabolismo , Extractos Vegetales/químicaRESUMEN
Paradoxically, some TRPV1 agonists are, at the organismal level, both nonpungent and clinically useful as topical analgesics. Here, we describe the scaled-up synthesis and characterization in mouse models of a novel, nonpungent vanilloid. Potent analgesic activity was observed in models of neuropathic pain, and the compound blocked capsaicin induced allodynia, showing dermal accumulation with little transdermal absorption. Finally, it displayed much weaker systemic toxicity compared to capsaicin and was negative in assays of genotoxicity.
Asunto(s)
Analgésicos/uso terapéutico , Compuestos de Fenilurea/uso terapéutico , Canales Catiónicos TRPV/agonistas , Tiazoles/uso terapéutico , Analgésicos/síntesis química , Analgésicos/farmacocinética , Analgésicos/toxicidad , Animales , Células CHO , Capsaicina , Cricetulus , Descubrimiento de Drogas , Hiperalgesia/inducido químicamente , Hiperalgesia/tratamiento farmacológico , Ratones Endogámicos ICR , Neuralgia/tratamiento farmacológico , Compuestos de Fenilurea/síntesis química , Compuestos de Fenilurea/farmacocinética , Compuestos de Fenilurea/toxicidad , Porcinos , Tiazoles/síntesis química , Tiazoles/farmacocinética , Tiazoles/toxicidadRESUMEN
This article has been retracted: please see Elsevier Policy on Article Withdrawal (https://www.elsevier.com/about/our-business/policies/article-withdrawal). This article has been retracted at the request of the Editor. After a thorough investigation, the Editor has concluded that the acceptance of this article was partly based upon the positive advice of one illegitimate reviewer report. The report was submitted from an email account which was provided by the corresponding author as a suggested reviewer during the submission of the article. Although purportedly a real reviewer account, the Editor has concluded that this was not of an appropriate, independent reviewer. This manipulation of the peer-review process represents a clear violation of the fundamentals of peer review, our publishing policies, and publishing ethics standards. Apologies are offered to the reviewer whose identity was assumed and to the readers of the journal that this deception was not detected during the submission process.
Asunto(s)
Acanthaceae/química , Analgésicos/síntesis química , Oro/química , Nanopartículas del Metal/química , Plata/química , Acanthaceae/metabolismo , Ácido Acético/toxicidad , Analgésicos/farmacología , Analgésicos/uso terapéutico , Animales , Tecnología Química Verde , Nanopartículas del Metal/uso terapéutico , Ratones , Ratones Endogámicos BALB C , Relajación Muscular/efectos de los fármacos , Atención de Enfermería , Dolor/inducido químicamente , Dolor/tratamiento farmacológico , Manejo del Dolor/métodos , Extractos Vegetales/química , Hojas de la Planta/química , Hojas de la Planta/metabolismoRESUMEN
Flavonoids are phenolic compounds that have always attracted pharmaceutical researchers and food manufacturers. Nature has indirectly provided us flavones in our daily diet i.e. tea, fruits, juices and vegetables. Flavones have got special position in research field of natural and synthetic organic chemistry due to their biological capabilities. Three substituted flavone derivatives have been synthesized from substituted O-hydroxy acetophenones and 4-trifluoromethyl benzaldehyde in good yield. The structures have been established by different spectroscopic techniques like 1HNMR 13CNMR, IR spectroscopy. The compounds were then screened for their enzyme inhibition potential and antinociceptive response in mice models with writhings induced by acetic acid, tail immersion and formalin-induced nociception assay procedures and structure activity relationship was established. The effects following pretreatment with naloxone were also studied to reveal the involvement of opioid receptors in the antinociceptive action. The flavone derivatives showed moderate to weak inhibition against LOX. Moreover, significant to moderate decrease in the number of abdominal constrictions, increase in paw-licking response time in both phases and a significant raise in latency time in nociception models. Moreover, the antinociceptive response was significantly attenuated by pretreatment with opioid receptor antagonist suggesting the involvement of opioidergic system in the analgesic action. The flavone derivatives showed analgesic response in all models of nociception suggesting the possible involvement of opioidergic system in the antinociceptive action.
Asunto(s)
Analgésicos/química , Analgésicos/farmacología , Flavonoides/química , Flavonoides/farmacología , Dolor/tratamiento farmacológico , Analgésicos/síntesis química , Animales , Cristalografía por Rayos X , Evaluación Preclínica de Medicamentos/métodos , Femenino , Flavonoides/síntesis química , Inhibidores de la Lipooxigenasa/síntesis química , Inhibidores de la Lipooxigenasa/química , Inhibidores de la Lipooxigenasa/farmacología , Espectroscopía de Resonancia Magnética , Masculino , Ratones , Estructura Molecular , Morfina/farmacología , Naloxona/farmacología , Antagonistas de Narcóticos/farmacología , Dolor/etiología , Espectrofotometría Infrarroja , Pruebas de Toxicidad AgudaRESUMEN
BACKGROUND AND OBJECTIVE: N-aryl derivatives of phthalimide and 4-nitro phthalimide have demonstrated cyclooxygenase inhibitory activity. Also, they possess excellent analgesic and antiinflammatory activity. In this work, a new series of N-arylmethylideneamino derivatives of phthalimide and 4-nitro phthalimide were designed and synthesized. METHODS: The designed compounds were synthesized by condensation of the appropriate aldehyde and N-aminophthalimide in ethanol at room temperature at PH around 3. Their analgesic and antiinflammatory activity were evaluated by acetic acid-induced pain test and carrageenan-induced paw edema test in mice and rats, respectively. RESULTS AND CONCLUSION: The details of the synthesis and chemical characterization of the analogs are described. In vivo screening showed compounds 3a, 3b, 3f and 3h were the most potent analgesic compounds. In addition, compounds 3a, 3c, 3d, 3e and 3j indicated comparable anti-inflammatory activity to indomethacin as a reference drug.
Asunto(s)
Analgésicos/síntesis química , Analgésicos/farmacología , Inhibidores de la Ciclooxigenasa 2/síntesis química , Inhibidores de la Ciclooxigenasa 2/farmacología , Diseño de Fármacos , Ftalimidas/química , Ftalimidas/farmacología , Animales , Evaluación Preclínica de Medicamentos , Masculino , Ratones , Ftalimidas/síntesis química , Espectroscopía de Protones por Resonancia Magnética , Ratas , Ratas Sprague-Dawley , Espectrofotometría InfrarrojaRESUMEN
In the present study, the synthesis of new selenoethers from nucleophilic substitution reaction between organyl halides and nucleophilic species of selenium generated in situ was demonstrated. After, this method was applied for the synthesis of pyridylselenides glycerol derivatives 9b and 9c and the antinociceptive and anti-inflammatory effects, as well as, acute toxicity were evaluated. In the formalin test, the compound 9b caused a reduction in licking time in both phases. Compounds 9b and 9c increased the latency to response in the hot-plate test and reduced the licking time induced by glutamate. Our results revealed the involvement of the nitrergic and/or glutamatergic pathways in the antinociceptive action of the compounds. Additionally, 9b and 9c did not cause any toxicity signals and oxidative stress parameters were not modified by treatments. Here, it was developed an alternative and efficient method for the synthesis of selenoethers glycerol derivatives. Furthermore, we demonstrated that this class is indeed interesting for the research of new drugs. Graphical Abstract á .
Asunto(s)
Éteres/química , Ácido Glutámico/metabolismo , Glicerol/síntesis química , Glicerol/farmacología , Óxido Nítrico/metabolismo , Dolor/tratamiento farmacológico , Selenio/química , Analgésicos/síntesis química , Analgésicos/química , Analgésicos/farmacología , Analgésicos/uso terapéutico , Animales , Antiinflamatorios/síntesis química , Antiinflamatorios/química , Antiinflamatorios/farmacología , Antiinflamatorios/uso terapéutico , Técnicas de Química Sintética , Glicerol/química , Glicerol/uso terapéutico , Inflamación/tratamiento farmacológico , Inflamación/metabolismo , Masculino , Ratones , Dolor/metabolismoRESUMEN
The benzylideneacetophenone derivative JC3 [(2E)-3-(4-hydroxy-3-methoxyphenyl)phenylpro-2-en-l-one] (JC3) was synthesized by modifying yakuchinone B obtained from the seeds of Alpinia oxyphylla, a member of the ginger family (Zingiberaceae), which are widely used as a folk remedy and as an anti-inflammatory. The aim of this study was to investigate the anti-arthritic effects of JC3 in rat models of carrageenan-induced paw pain and carrageenan/kaolin-induced knee arthritis. The anti-nociceptive effect of JC3 was assessed by measuring paw withdrawal pressure thresholds using an analgesy-meter. Arthritic symptoms in our monoarthritic rat model were evaluated using weight distribution ratios (WDR), paw thicknesses, and serum prostaglandin E2 (PGE2), tumor necrosis factor (TNF)-α, interleukin (IL)-6, and vascular endothelial growth factor (VEGF) levels (determined by ELISA). Histological analyses of knee joints were performed after injecting JC3 intraperitoneally into rats before carrageenan treatment at 5 or 10 mg/kg/day for 6 days. The anti-inflammatory effects of JC3 were investigated in vitro using interleukin-1beta (IL-1ß)-stimulated fibroblast-like synoviocytes (FLS) derived from arthritis patients. PGE2, IL-6, and IL-8 levels were measured after treating FLS with JC3. In arthritis-induced rats, JC3 treatment significantly decreased nociceptive and arthritic symptoms at days 5 to 6 after carrageenan/kaolin injection. Histological staining of knee tissue showed that JC3 significantly reduced inflammatory areas in the knee joints. Furthermore, JC3 inhibited the expressions of IL-6 and IL-8 in FLS cells at concentrations of 5-10 µg/ml and decreased PGE2 levels in FLS cells. These findings suggest JC3 has anti-arthritic effects in in vivo and in vitro, and that it might be useful for the treatment of arthritis.
Asunto(s)
Artritis Experimental/tratamiento farmacológico , Compuestos de Bencilideno/farmacología , Citocinas/antagonistas & inhibidores , Inflamación/prevención & control , Sinoviocitos/metabolismo , Analgésicos/síntesis química , Analgésicos/farmacología , Animales , Antiinflamatorios/síntesis química , Antiinflamatorios/farmacología , Artritis Experimental/inducido químicamente , Compuestos de Bencilideno/uso terapéutico , Carragenina , Citocinas/metabolismo , Humanos , Interleucina-1beta , Caolín , Propiofenonas/síntesis química , Ratas , Sinoviocitos/efectos de los fármacos , Sinoviocitos/patologíaRESUMEN
In the present study, some new analogues of VV-hemorphin-5, modified at position 1 and 7 by the non-proteinogenic and/or natural amino acids followed the structures Xxx-Val-Val-Tyr-Pro-Trp-Thr-Gln-NH2 and Val-Val-Tyr-Pro-Trp-Thr-Yyy-NH2, where Xxx is Ile or Aib and Yyy is Lys/Orn/Dap/Dab were synthesized to investigate their potential antinociceptive activities. We report also the redox potentials and the acid/base properties as pKa values of these peptide analogues which were compared toward electrochemical behaviour of tryptophan containing peptides. All analogues showed a short lasting initial antinociceptive effect, however H2 hemorphin analogue is characterized with prolong and strong antinociceptive effect, while the other peptide analogues exerted more variable effects on the visceral nociception depending on the dose or time after the intracerebral injection.
Asunto(s)
Aminoácidos/farmacología , Analgésicos/farmacología , Conducta Animal/efectos de los fármacos , Hemoglobinas/farmacología , Dolor/tratamiento farmacológico , Fragmentos de Péptidos/farmacología , Aminoácidos/administración & dosificación , Aminoácidos/química , Analgésicos/síntesis química , Analgésicos/química , Animales , Relación Dosis-Respuesta a Droga , Evaluación Preclínica de Medicamentos , Hemoglobinas/síntesis química , Hemoglobinas/química , Infusiones Intraventriculares , Ratones , Estructura Molecular , Dimensión del Dolor , Fragmentos de Péptidos/síntesis química , Fragmentos de Péptidos/química , Relación Estructura-ActividadRESUMEN
Pain and inflammation are complex clinical conditions that are present in a wide variety of disorders. Most drugs used to treat pain and inflammation have potential side effects, which makes it necessary to search for new sources of bioactive molecules. In this paper, we describe the ability of LASSBio-1586, an N-acylhydrazone derivative, to attenuate nociceptive behavior and the inflammatory response in mice. Antinociceptive activity was evaluated through acetic acid-induced writhing and formalin-induced nociception tests. In these experimental models, LASSBio-1586 significantly (p<0.05) reduced nociceptive behavior. Several methods of acute and chronic inflammation induced by different chemical (carrageenan, histamine, croton oil, arachidonic acid) and physical (cotton pellet) agents were used to evaluate the anti-inflammatory effect of LASSBio-1586. LASSBio-1586 exhibited potent anti-inflammatory activity in all tests (p<0.05). Study of the mechanism of action demonstrated the possible involvement of the nitrergic, serotonergic and histamine signaling pathways. In addition, a molecular docking study was performed, indicating that LASSBio-1586 is able to block the COX-2 enzyme, reducing arachidonic acid metabolism and consequently decreasing the production of prostaglandins, which are important inflammatory mediators. In summary, LASSBio-1586 exhibited relevant antinociceptive and anti-inflammatory potential and acted on several targets, making it a candidate for a new multi-target oral anti-inflammatory drug.